HistoIndex, a Singapore-based developer of AI-driven digital pathology solutions for chronic liver disease, said on Tuesday that it has formed a strategic partnership with Houston Research Institute (HRI), a US research institute focused on conducting clinical trials in hepatology and gastroenterology.

Through commercial partnerships, HistoIndex provides advanced diagnostic testing services to patients with Metabolic Dysfunction-associated Steatohepatitis (MASH), supporting more precise disease assessment and clinical decision-making.

Under the new partnership, all four HRI medical centres -- Houston Research Institute Pasadena, Houston Research Institute Sugar Land, Houston Research Institute, and Houston Research Institute Medical Center -- will have access to HistoIndex's integrated diagnostic offering, which combines expert histopathological evaluation by experienced pathologists with advanced AI-based biopsy analysis.

To complement standard-of-care histological evaluation of MASH, for steatosis, lobular inflammation, ballooning and fibrosis, HistoIndex will also offer its proprietary AI-based diagnostic test, FibroSIGHT Plus, which delivers fully quantitative assessment of liver fibrosis in MASH liver biopsies.